Efficiency of IL-2 and IL-15 combined use for activation of cytotoxic lymphocytes in vitro



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

0ne of the modern approaches for cancer treatment is based on the application of immunotherapy using activated cytotoxic lymphocytes. Search of methodological approaches for the preparation of activated lymphocytes in vitro is relevant. As a result of this study, the method for activation and culturing of lymphocytes for cancer patients have been perfected using cytokine IL-2 and IL-15. Peripheral mononuclear cells of cancer patients were culture using two different mediums based on RPMi-1640 with IL-2 for 10 days and X-vivo20 supplemented with IL-2 and IL-15 for 14 days. The expression of activation markers (CD38, CD69, CD25, HLA-DR and CD314) and subpopulations of lymphocytes were evaluated by the method of flow cytometry every 2 days. The expression of activation markers of lymphocytes increased after 3 days of culture in the first medium and after 5 days in the second one. We revealed that the activation of lymphocytes was faster in medium based on RPMI with IL-2, but the proliferation and viability of lymphocytes were lower than in the second medium. The culture medium based on RPMI with IL-2 can be recommended for more quickly obtaining of lymphokine-activated killer cells. The medium based on X-vivo20 with a combination of IL-2 and IL-15 can be recommended for a longer cultivation of lymphocytes and for escalating of lymphokine-activated killer cells. it has been shown that the combination of cytokines IL-2 and IL-15 not only has a positive influence on the proliferation activity of the lymphocytes and the expression of activation markers, but also on their viability.

Full Text

Restricted Access

About the authors

E. V Abakushina

A. Tsyb Medical Radiological Research Centre - branch of the National Medical Research Radiological Centre

Email: abakushina@mail.ru

Yu. V Marizina

A. Tsyb Medical Radiological Research Centre - branch of the National Medical Research Radiological Centre

G. S Neprina

A. Tsyb Medical Radiological Research Centre - branch of the National Medical Research Radiological Centre

References

  1. Бережной А.Е., Гнучев Н.В., Георгиев Г.П. и др. Молекулярные механизмы взаимодействия опухоли и иммунной системы Вопр. онкол. 2008; 54(6): 669-83.
  2. Абакушина Е.В., Кузьмина Е.Г., Коваленко Е.И. Основные свойства и функции NK-клеток человека. Иммунол. 2012; 33(4): 220-4
  3. Закеева И.Р., Бережной А.Е., Гнучев Н.В. и др. Ингибиторные рецепторы лимфоцитов и их роль в противоопухолевом иммунитете. Вопр. онкол. 2007; 53(2): 140-9.
  4. Sabry M., Lowdell M.W. Tumor-primed NK cells: waiting for the green light. Front. Immunol. 2013; 4(408): 1-7.
  5. Shen Y., Lu C., Tian W. et al. Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer. Int. J. Oncol. 2012; 40(4): 1285-90.
  6. Курилин В.В., Хантакова Ю.Н., Облеухова И.А. и др. Стимуляция дендритными клетками in vitro противоопухолевой цитотоксической активности мононуклеарных клеток больных колоректальным раком. Мед. иммунол. 2013; 15(3): 235-46.
  7. Нехаева Т.Л. Оптимизация аутологичных дендритно-клеточных вакцин для лечения больных злокачественными новообразованиями. Сиб. онкол. журн. 2013; 57(3): 52-6.
  8. Титов К.С., Киселевский М.В., Демидов Л.В. и др. Внутрибрюшинная биотерапия с использованием ИЛ-2 и донорских ЛАК-клеток при метестатических асцитах у больных раком яичников. Росс. биотерапевт. журн. 2011; 10(2): 51-4.
  9. Георгиев Г.П., Ларин С.С., Сащенко Л.П. и др. Вакцинотерапия опухолей модифицированными геном TAG7 опухолевыми клетками. Молекул. мед. 2008; 4: 1-9.
  10. Cheng M., Chen Y., Xiao W. et al. NK cell-based immunotherapy for malignant diseases. Cell. Mol. Immunol. 2013; 3(10): 1-23.
  11. Kimura H., Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997; 80(1): 42-9.
  12. Todaro M., Orlando V., Cicero G. et al. Chemotherapy sensitizes colon cancer initiating cells to Vy9VS2 T cell-mediated cytotoxicity. PloS One. 2013; 6(8): 1-8.
  13. Sangiolo D., Martinuzzi E., Todorovic M. et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int. Immunol. 2008; 20(7): 841-8.
  14. Boiardi A., Silvani A., Ruffini P.A. et al. Locoregional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol. Immunother. 1994; 39(3): 193-7.
  15. Wang F.S., Liu M.X., Zhang B. et al. Antitumor activities of human autologous cytokineinduced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J. Gastroenterol. 2002; 8(3): 464-8.
  16. Литвинова Л.С., Гуцол А.А., Сохоневич Н.А. и др. Основные поверхностные маркеры функциональной активности Т-лимфоцитов Мед. иммунол. 2014; 16(1): 7-26.
  17. Sandoval-Montes C., Santos-Argumedo L. CD38 is expressed selectively during the activation of a subset of mature T-cells with redused proliferation but improved potential to produce cytokines. Leukocyte Biol. 2005; (77): 513-21.
  18. Clausen J., Vergeiner B., Enk M. et al. Functional significance of the activation-associated receptor CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiol. 2003; 207(2): 85-93.
  19. Чикилева И.О., Анисимова Н.Ю., Верескунова Н.В. и др.; ЗАО «БИОКАД». Способ получения активированных лейкоцитов для адъювантной адаптивной иммунотерапии злокачественных новообразований. Патент РФ 2414915. 27. 03. 2011.
  20. Киселевский М.В. Адоптивная иммунотерапия при злокачественных новообразованиях. Вест. РАН. 2003; (1): 40-4.
  21. Koyama S. Augmented human-tumorocytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/ tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma. J. Cancer Res. Clin. Oncol. 1997; 123(9): 478-84.
  22. Демидов Л.В., Михайлова И.Н., Синельников И.Е. и др. Проблемы клинического применения ИЛ-2/ЛАК-терапии. Росс. Биотерапевт. журн. 2005; 4(4): 29-37.
  23. Яковлев В.Н., Зыков Д.В., Алексеев В.Г. и др.; Яковлев В. Н. Способ лечения больных раком легкого. Патент РФ 2500435. 10. 12. 2013.
  24. Киселевский М.В., Анисимова Н.Ю., Соснов А.В.; Российский онкологический научный центр им. Н.Н. Блохина РАМН. Способ получения активированных мононуклеарных лейкоцитов. Патент РФ 2402338. 27. 10. 2010.
  25. Абакушина Е.В. Определение функциональной активности естественных киллеров человека методом проточной цитофлуориметрии. Клинико-лаб. консил. 2011; 39(3): 17-25.
  26. Абакушина Е.В. Влияние углеводов, представленных на поверхности клеток-мишеней, на цитолитическую активность естественных киллеров человека [диссертация]. Москва; РГМУ; 2002
  27. De Maria A., Bozzano F., Cantoni C. et al. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16 + NK cells as rapid producers of abundant iFN-gamma on activation. PNAS USA. 2011; (108): 728-32.
  28. Lin S.J., Lee P.T., Kuo M.L. Cytokine activation of natural killer cells. Methods Mol. Biol. 2014; (1139): 223-9.
  29. Rodella L., Zamai L., Rezzani R. et al. interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells. Br. J. Haematol. 2001; 115(2): 442-50.
  30. Naora H., Gougeon M. Activation, survival and apoptosis of CD45R0+ and CD45R0- T cells of human immunodeficiency virus-infected individuals: effects of interleukin-15 and comparison with interleukin-2. immunology 1999; 97(2): 181-7.
  31. Litvinova L.S., Sokhonevich N.A., Gutsol A.A. et al. influence of immunoregulatory cytokines (iL-2, iL-7 and iL-15) in vitro upon activation, proliferation and apoptosis of immune memory T-cells]. Tsitologiia 2013; 55(8): 566-71.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies